|
시장보고서
상품코드
2008099
설트랄린 염산염 시장 : 종류별, 용도별, 유통 채널별, 지역별Sertraline HCl Market, By Type, By Application, By Distribution Channel, By Geography |
||||||
설트랄린 염산염 시장은 2026년에 21억 달러로 추정되며, 2033년까지 31억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.1%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 21억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 4.10% | 예측 금액(2033년) | 31억 달러 |
설트랄린 염산염은 선택적 세로토닌 재흡수 억제제(SSRI)로 알려진 항우울제의 일종입니다. 설트랄린 염산염은 다른 SSRI와 유사한 작용기전을 가지고 있습니다. 뇌에서 사용할 수 있는 세로토닌의 양을 증가시켜 작용합니다. 세로토닌은 신경전달물질, 즉 화학적 메신저로 기분, 수면, 보상, 학습, 기억 등 인간의 일상생활의 많은 요소들을 조절하는 데 관여합니다. 연구에 따르면 우울증은 세로토닌 농도의 감소와 관련이 있는 것으로 나타났습니다. 설트랄린은 뇌의 세로토닌 양을 증가시켜 화학적 균형 장애를 완화하고 전반적인 기분을 개선하는 데 도움을 줍니다. 설트랄린은 경구용 정제 또는 액상 형태로 제공됩니다. 보통 1일 1회, 아침 또는 저녁에 복용합니다. 월경 전 불쾌감 장애를 치료하기 위해 매일 복용하는 경우도 있고, 월경 주기의 특정 날에만 복용하는 경우도 있습니다.
시장 역학
주요 시장 동향으로는 항우울제 처방률과 지출 증가가 있으며, 이는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 2021년 3월 Springer Nature Switzerland AG가 발표한 기사에 따르면, COVID-19 팬데믹 기간(2020년 1월부터 12월까지) 동안 항우울제(AD) 처방 건수는 총 7,800만 건으로 2019년 대비 400만 건이 증가했다고 합니다. 이로 인해 영국의 공공 의료 시스템인 국민보건서비스(NHS)의 비용은 2019년 대비 1억 3,900만 파운드(1억 7,070만 달러)가 증가했습니다. SSRI 계열 항우울제인 설트랄린만 해도 2020년 비용은 2019년 대비 1억 1,300만 파운드(1억 3,870만 달러)가 증가했습니다.
본 보고서의 주요 특징
- 세계의 설트랄린 염산염 시장에 대해 조사 분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 설트랄린 염산염 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계 설트랄린 염산염 시장" 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 설트랄린 염산염 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 설트랄린 염산염 시장 : 종류별(2026-2033년)
제5장 세계의 설트랄린 염산염 시장 : 용도별(2026-2033년)
제6장 세계의 설트랄린 염산염 시장 : 유통 채널별(2026-2033년)
제7장 세계의 설트랄린 염산염 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSM 26.04.30Sertraline Hcl Market is estimated to be valued at USD 2.1 Bn in 2026 and is expected to reach USD 3.1 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.1 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.10% | 2033 Value Projection: | USD 3.1 Bn |
Sertraline HCl belongs to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Sertraline HCl has the same mechanism of action as other SSRIs. It works by increasing the amount of serotonin that is available in the brain. Serotonin is a neurotransmitter, or chemical messenger, that is involved in regulating many elements of a person's daily life, including mood, sleep, rewards, learning, and memory. Research has linked depression with low levels of serotonin. Sertraline increases the amount of serotonin present in the brain, helping to reduce chemical imbalances and improve a person's overall mood. Sertraline is available as either an oral tablet or a liquid. Typically, a person takes a dose in the morning or evening, once a day. People using it to treat premenstrual dysphoric disorder may take it every day or only on select days of the month.
Market Dynamics
Key trends in the market include increasing prescription rate and expenditure for antidepressant drug which is expected to drive the market growth during the forecast period. For instance, according to an article published in Springer Nature Switzerland AG in March 2021, stated that the total number of Ads (antidepressants) prescriptions dispensed during COVID-19 pandemic (January to December 2020) were 78 million, 4 million more than in 2019 that costed the National Health Service (NHS) is the publicly funded healthcare system in England, £139 million (US $170.7 million) more than in 2019. Sertraline, an SSRI antidepressant drug, alone accounted for an extra £113 million (US $ 138.7 million) during 2020 than in 2019.
Key features of the study
- This report provides an in-depth analysis of the global sertraline HCl market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sertraline HCl market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Accord Biopharma, Apotex Inc., Aurobindo Pharma USA, InvaGen, Lupin, Camber Pharmaceuticals, Mylan (a part of Viatris Inc.), Sun Pharmaceutical, Wockhardt, Alpic Biotech
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sertraline HCl market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sertraline HCl market.
Market Segmentation
- By Type
- 25 mg
- 50 mg
- 100 mg
- Others
- By Application
- Obsessive-Compulsive Disorder
- Depression
- Panic Disorder
- Premenstrual Dysphoric Disorder
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Accord Biopharma
- Apotex Inc.
- Aurobindo Pharma USA
- InvaGen
- Lupin
- Camber Pharmaceuticals
- Mylan N.V. (a Part of Viatris Inc.)
- Sun Pharmaceutical
- Wockhardt
- Alpic Biotech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By Distribution channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
4. Global Sertraline HCL Market, By Type, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- 25 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- 100 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Sertraline HCL Market, By Application, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Obsessive-Compulsive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Panic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Premenstrual Dysphoric Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Sertraline HCL Market, By Distribution channel, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Sertraline HCL Market, By Region, 2026-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Accord Biopharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurobindo Pharma USA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- InvaGen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Camber Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V. (a part of Viatris Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Wockhardt
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alpic Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
9. Section
- Research Methodology
- About us
